Darmstadt, Germany: Phase III MANEUVER study met primary endpoint, with an objective response rate at week 25 of 54.0% for pimicotinib versus 3.2% for placebo (p<0.0001) Statistically significant and clinically meaningful improvements also seen in all key secondary endpoints, including pain and stiffness Oral, once-daily treatment with pimicotinib was well-tolerated, …
